Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines

Geoffrey Stone, Suzanne Barzee, Victoria Snarsky, Kristin Kee, Celsa A. Spina, Xiao Fang Yu, Richard S. Kornbluth

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

For use in humans, human immunodeficiency virus (HIV) DNA vaccines may need to include immunostimulatory adjuvant molecules. CD40 ligand (CD40L), a member of the tumor necrosis factor (TNF) superfamily (TNFSF), is one candidate adjuvant, but it has been difficult to use because it is normally expressed as a trimeric membrane molecule. Soluble trimeric forms of CD40L have been produced, but in vitro data indicate that multimeric, many-trimer forms of soluble CD40L are more active. This multimerization requirement was evaluated in mice using plasmids that encoded either 1-trimer, 2-trimer, or 4-trimer soluble forms of CB40L. Fusion with the body of Acrp30 was used to produce the 2-trimer form, and fusion with the body of surfactant protein D was used to produce the 4-trimer form. Using plasmids for secreted HIV-1 antigens Gag and Env, soluble CD40L was active as an adjuvant in direct proportion to the valence of the trimers (1 < 2 < 4). These CD40L-augmented DNA vaccines elicited strong CD8+ T-cell responses but did not elicit significant CD4- T-cell or antibody responses. To test the applicability of the multimeric fusion protein approach to other TNFSFs, a 4-trimer construct for the ligand of glucocorticoid-induced TNF family-related receptor (GITR) was also prepared. Multimeric soluble GITR ligand (GITRL) augmented the CD8+ T-cell, CD4+ T-cell, and antibody responses to DNA vaccination. In summary, multimeric CD40L and GITRL are new adjuvants for DNA vaccines. Plasmids for expressing multimeric TNFSF fusion proteins permit the rapid testing of TNFSF molecules in vivo.

Original languageEnglish
Pages (from-to)1762-1772
Number of pages11
JournalJournal of Virology
Volume80
Issue number4
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

CD40 Ligand
DNA Vaccines
Human immunodeficiency virus
recombinant vaccines
glucocorticoids
Glucocorticoids
adjuvants
HIV
Ligands
receptors
T-Lymphocytes
Plasmids
T-lymphocytes
Antibody Formation
plasmids
Tumor Necrosis Factor-alpha
tumor necrosis factors
Pulmonary Surfactant-Associated Protein D
env Gene Products
gag Gene Products

ASJC Scopus subject areas

  • Immunology

Cite this

Stone, G., Barzee, S., Snarsky, V., Kee, K., Spina, C. A., Yu, X. F., & Kornbluth, R. S. (2006). Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. Journal of Virology, 80(4), 1762-1772. https://doi.org/10.1128/JVI.80.4.1762-1772.2006

Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. / Stone, Geoffrey; Barzee, Suzanne; Snarsky, Victoria; Kee, Kristin; Spina, Celsa A.; Yu, Xiao Fang; Kornbluth, Richard S.

In: Journal of Virology, Vol. 80, No. 4, 01.02.2006, p. 1762-1772.

Research output: Contribution to journalArticle

Stone, G, Barzee, S, Snarsky, V, Kee, K, Spina, CA, Yu, XF & Kornbluth, RS 2006, 'Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines', Journal of Virology, vol. 80, no. 4, pp. 1762-1772. https://doi.org/10.1128/JVI.80.4.1762-1772.2006
Stone, Geoffrey ; Barzee, Suzanne ; Snarsky, Victoria ; Kee, Kristin ; Spina, Celsa A. ; Yu, Xiao Fang ; Kornbluth, Richard S. / Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. In: Journal of Virology. 2006 ; Vol. 80, No. 4. pp. 1762-1772.
@article{02cefcf4a3e649c3ac356474a9eac440,
title = "Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines",
abstract = "For use in humans, human immunodeficiency virus (HIV) DNA vaccines may need to include immunostimulatory adjuvant molecules. CD40 ligand (CD40L), a member of the tumor necrosis factor (TNF) superfamily (TNFSF), is one candidate adjuvant, but it has been difficult to use because it is normally expressed as a trimeric membrane molecule. Soluble trimeric forms of CD40L have been produced, but in vitro data indicate that multimeric, many-trimer forms of soluble CD40L are more active. This multimerization requirement was evaluated in mice using plasmids that encoded either 1-trimer, 2-trimer, or 4-trimer soluble forms of CB40L. Fusion with the body of Acrp30 was used to produce the 2-trimer form, and fusion with the body of surfactant protein D was used to produce the 4-trimer form. Using plasmids for secreted HIV-1 antigens Gag and Env, soluble CD40L was active as an adjuvant in direct proportion to the valence of the trimers (1 < 2 < 4). These CD40L-augmented DNA vaccines elicited strong CD8+ T-cell responses but did not elicit significant CD4- T-cell or antibody responses. To test the applicability of the multimeric fusion protein approach to other TNFSFs, a 4-trimer construct for the ligand of glucocorticoid-induced TNF family-related receptor (GITR) was also prepared. Multimeric soluble GITR ligand (GITRL) augmented the CD8+ T-cell, CD4+ T-cell, and antibody responses to DNA vaccination. In summary, multimeric CD40L and GITRL are new adjuvants for DNA vaccines. Plasmids for expressing multimeric TNFSF fusion proteins permit the rapid testing of TNFSF molecules in vivo.",
author = "Geoffrey Stone and Suzanne Barzee and Victoria Snarsky and Kristin Kee and Spina, {Celsa A.} and Yu, {Xiao Fang} and Kornbluth, {Richard S.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1128/JVI.80.4.1762-1772.2006",
language = "English",
volume = "80",
pages = "1762--1772",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Multimeric soluble CB40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines

AU - Stone, Geoffrey

AU - Barzee, Suzanne

AU - Snarsky, Victoria

AU - Kee, Kristin

AU - Spina, Celsa A.

AU - Yu, Xiao Fang

AU - Kornbluth, Richard S.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - For use in humans, human immunodeficiency virus (HIV) DNA vaccines may need to include immunostimulatory adjuvant molecules. CD40 ligand (CD40L), a member of the tumor necrosis factor (TNF) superfamily (TNFSF), is one candidate adjuvant, but it has been difficult to use because it is normally expressed as a trimeric membrane molecule. Soluble trimeric forms of CD40L have been produced, but in vitro data indicate that multimeric, many-trimer forms of soluble CD40L are more active. This multimerization requirement was evaluated in mice using plasmids that encoded either 1-trimer, 2-trimer, or 4-trimer soluble forms of CB40L. Fusion with the body of Acrp30 was used to produce the 2-trimer form, and fusion with the body of surfactant protein D was used to produce the 4-trimer form. Using plasmids for secreted HIV-1 antigens Gag and Env, soluble CD40L was active as an adjuvant in direct proportion to the valence of the trimers (1 < 2 < 4). These CD40L-augmented DNA vaccines elicited strong CD8+ T-cell responses but did not elicit significant CD4- T-cell or antibody responses. To test the applicability of the multimeric fusion protein approach to other TNFSFs, a 4-trimer construct for the ligand of glucocorticoid-induced TNF family-related receptor (GITR) was also prepared. Multimeric soluble GITR ligand (GITRL) augmented the CD8+ T-cell, CD4+ T-cell, and antibody responses to DNA vaccination. In summary, multimeric CD40L and GITRL are new adjuvants for DNA vaccines. Plasmids for expressing multimeric TNFSF fusion proteins permit the rapid testing of TNFSF molecules in vivo.

AB - For use in humans, human immunodeficiency virus (HIV) DNA vaccines may need to include immunostimulatory adjuvant molecules. CD40 ligand (CD40L), a member of the tumor necrosis factor (TNF) superfamily (TNFSF), is one candidate adjuvant, but it has been difficult to use because it is normally expressed as a trimeric membrane molecule. Soluble trimeric forms of CD40L have been produced, but in vitro data indicate that multimeric, many-trimer forms of soluble CD40L are more active. This multimerization requirement was evaluated in mice using plasmids that encoded either 1-trimer, 2-trimer, or 4-trimer soluble forms of CB40L. Fusion with the body of Acrp30 was used to produce the 2-trimer form, and fusion with the body of surfactant protein D was used to produce the 4-trimer form. Using plasmids for secreted HIV-1 antigens Gag and Env, soluble CD40L was active as an adjuvant in direct proportion to the valence of the trimers (1 < 2 < 4). These CD40L-augmented DNA vaccines elicited strong CD8+ T-cell responses but did not elicit significant CD4- T-cell or antibody responses. To test the applicability of the multimeric fusion protein approach to other TNFSFs, a 4-trimer construct for the ligand of glucocorticoid-induced TNF family-related receptor (GITR) was also prepared. Multimeric soluble GITR ligand (GITRL) augmented the CD8+ T-cell, CD4+ T-cell, and antibody responses to DNA vaccination. In summary, multimeric CD40L and GITRL are new adjuvants for DNA vaccines. Plasmids for expressing multimeric TNFSF fusion proteins permit the rapid testing of TNFSF molecules in vivo.

UR - http://www.scopus.com/inward/record.url?scp=32444446901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444446901&partnerID=8YFLogxK

U2 - 10.1128/JVI.80.4.1762-1772.2006

DO - 10.1128/JVI.80.4.1762-1772.2006

M3 - Article

C2 - 16439533

AN - SCOPUS:32444446901

VL - 80

SP - 1762

EP - 1772

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 4

ER -